Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

An exploratory pooled analysis of the Phase 3 METREX, METREO, and MATINEE trials has demonstrated that mepolizumab (Nucala; GSK) consistently reduced the annualized rate of moderate or severe exacerbations in people with 

 (COPD) compared with placebo, regardless of blood eosinophil count (BEC) variability pattern.

Mepolizumab was approved by the United States (US) Food and Drug Administration (FDA) in May 2025 as an add-on maintenance treatment for patients with COPD with an eosinophilic phenotype.

 BECs are an established biomarker of type 2 inflammation in COPD and are associated with increased exacerbation risk. Yet BEC levels are dynamic, influenced by infections, corticosteroid exposure, circadian variation, and other factors. Real-world data suggest that only 5–18% of patients demonstrate persistently high BEC ≥300 cells/µL, while nearly 30% exhibit intermittent elevations. This variability complicates clinical decision-making and raises important questions about how to identify patients most likely to benefit from biologic therapy.

The analysis, presented by Gerald Criner, MD, Chair and Professor of Thoracic Medicine and Surgery at Lewis Katz School of Medicine at Temple University, at the 

American Academy of Allergy, Asthma & Immunology (AAAAI)

 2026 Annual Meeting held in Philadelphia, Pennsylvania, valuated mepolizumab 100 mg subcutaneously versus placebo in patients ≥40 years of age with COPD receiving inhaled triple therapy. Patients were stratified by longitudinal pre-randomization BEC patterns to assess whether variability in eosinophil levels influences response.

Criner and colleaguges found that across patients with evidence of type 2 inflammation, mepolizumab consistently reduced the annualized rate of moderate or severe exacerbations compared with placebo, regardless of BEC variability pattern.

In Subgroup 1 (BEC ≥300 cells/µL at screening and baseline), exacerbation rates were reduced from 1.31 events/year with placebo to 0.95 with mepolizumab (rate ratio [RR], 0.73; 95% CI 0.61–0.88), corresponding to a 27% relative risk reduction.

Subgroup 2 (persistently ≥300 cells/µL across all pre-randomization timepoints) showed a numerical reduction from 1.11 to 0.97 events/year (RR, 0.88; 95% CI 0.70–1.11), equating to a 12% relative risk reduction.

Subgroup 3, (high type 2 inflammation at screening [≥300 cells/µL] but short-term variability [<300 cells/µL at baseline]), experienced a decrease from 1.27 to 0.99 events/year (RR, 0.78; 95% CI 0.60–1.01), representing a 22% relative risk reduction.

Notably, Subgroup 4 (≥300 cells/µL at any pre-randomization timepoint with at least one measurement <150 cells/µL) demonstrated one of the largest treatment effects. Exacerbation rates declined from 1.43 to 0.91 events/year (RR, 0.64; 95% CI 0.45–0.89), corresponding to a 36% relative risk reduction. This subgroup also had among the highest placebo exacerbation rates, suggesting that patients with marked BEC variability may represent a particularly high-risk and responsive phenotype.

Patients meeting the US-approved eosinophilic phenotype definition (Subgroup 5: ≥150 cells/µL at screening and/or ≥300 cells/µL in the prior year) experienced a reduction from 1.36 to 1.10 events/year (RR, 0.81; 95% CI 0.72–0.91), a 19% relative risk reduction. Similar significant reductions were observed in Subgroup 6 (RR, 0.83; 17% risk reduction) and Subgroup 7 (RR, 0.79; 21% risk reduction).

In contrast, Subgroup 8 of non-type 2 COPD (persistently <150 cells/µL) showed no meaningful benefit; rates increased from 1.17 to 1.47 events/year (RR, 1.26; 95% CI 0.98–1.61), indicating no protective effect in the absence of type 2 inflammation.

For exacerbations requiring emergency department (ED) visit and/or hospitalization, results generally mirrored the moderate/severe findings, with efficacy across BEC levels except in Subgroup 8 in those without type 2 COPD Again, no meaningful benefit was observed (RR, 1.11; 95% CI 0.63–1.97).

Subgroup 3 demonstrated the largest relative reduction in severe outcomes, with rates decreasing from 0.27 to 0.12 events/year (RR, 0.44; 95% CI 0.25–0.80), representing a 56% relative risk reduction.

Subgroup 5 showed a reduction from 0.26 to 0.20 events/year (RR, 0.77; 95% CI 0.60–0.99), corresponding to a 23% relative risk reduction. Subgroups 6 and 7 demonstrated consistent directional improvements (RR, 0.77 and 0.76, reflecting 23% and 24% relative risk reductions, respectively).

Overall, this analysis supports the use of mepolizumab in patients with inadequately controlled COPD and documented type 2 inflammatory activity, consistent with its US-approved indication, and suggests that requiring persistent eosinophilia may unnecessarily exclude patients who could achieve meaningful risk reduction.

“Mepolizumab consistently reduces exacerbation rates in a wide spectrum of patients with COPD and type 2 inflammation versus placebo, both in those who have high and low variability in their BECsover time, as well as those with historically elevated BEC, prior to therapy initiation. These results support the use of mepolizumab in patients who have shown signsof type 2 inflammation, without necessarily being persistently eosinophilic,” Criner and colleagues wrote in their poster.

1. Criner GJ, Watz H, Han MK, et al. MepolizumabImproves Exacerbation Outcomes in Patients with COPD with Type 2 Inflammation and Variable Eosinophil Patterns. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Poster #L01.

2. Johnson V. FDA Approves Mepolizumab for Eosinophilic COPD. Article. HCPLive. May 22, 2025. 

https://www.hcplive.com/view/fda-approves-mepolizumab-for-eosinophilic-copd

Articles

Exploratory pooling of phase 3 METREX, METREO, and MATINEE evaluated mepolizumab 100 mg SC added to inhaled triple therapy in COPD patients ≥40 with type 2 inflammation. Despite substantial longitudinal blood eosinophil count (BEC) variability, mepolizumab reduced annualized moderate/severe exacerbations versus placebo across multiple BEC-pattern strata, including intermittent and highly variable eosinophilia. Largest effect occurred in those with any BEC ≥300 and at least one <150. No benefit was observed in persistently low BEC (<150) non–type 2 COPD. Severe ED/hospitalization events similarly declined in most type 2 strata.

A new study stratified patients by longitudinal BEC patterns to assess whether variability in eosinophil levels influences response.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Mepolizumab Reduces Type 2 COPD Exacerbations Across Variable BEC Levels

Matthew Krantz, MD, from Vanderbilt University Medical Center

HLA-A*32:01 Linked to Lamotrigine DRESS Risk, With Matthew Krantz, MD

New data presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia from February 27 – March 2, strengthen evidence that HLA-A*32:01 carriage is strongly associated with lamotrigine-induced drug reaction with 

eosinophilia and systemic symptoms (DRESS)

 in a US cohort. In an interview conducted at AAAAI, Matthew Krantz, MD, from Vanderbilt University Medical Center, discussed the clinical implications of the findings.

“This is really kind of a discovery HLA association given that HLA testing of class 1 and 2 alleles isn't done on a routine basis for all patients and integrated into their electronic health record,” Krantz said. “This kind of test may be most helpful at this point for helping assess causality for patients who experience stress where they're receiving multiple medications at the same time.”

Krantz explained that DRESS presents a particular diagnostic challenge because of its delayed onset. Symptoms typically emerge 2 to 8 weeks after a medication is started, a window during which patients are often exposed to multiple new therapies. This latency makes it difficult to confidently identify the true culprit drug and complicates decisions about which agents can be safely restarted.

“We want to precisely have them avoid medications that put them at risk of recurrent reactions,” he continued.

Investigators recognized antibiotics, allopurinol, and anti-seizure drugs are the main culprits of DRESS. The team sought to see whether HLA-A*32:01 could serve as a genetic predictor of lamotrigine-induced DRESS.

Krantz and colleagues conducted a prospectively identified, multi-institutional case-control study including patients from Vanderbilt University Medical Center (VUMC) and Mass General Brigham. The cohort comprised 30 lamotrigine-induced DRESS cases (RegiSCAR ≥4) and 300 matched lamotrigine-tolerant controls drawn from VUMC’s BioVU biobank, matched 10:1 by age, sex, and self-identified race.

The cases were predominantly female (87%) and largely self-identified White (93%), with a median age of 33 years (interquartile range, 25–56). High-resolution HLA class I typing was performed using Illumina MiSeq, supplemented by HLA imputation from genotyping array data (SNP2HLA). Association testing was conducted at the locus, haplotype, and amino acid levels using midasHLA and R software, with Bonferroni correction applied.

At the locus level, HLA-A*32:01 was strongly associated with lamotrigine-induced DRESS (odds ratio [OR], 12.1; 95% CI, 4.9–29.8; Pc < .001). Carriage rates were 40% among cases versus 5.5% among tolerant controls. No haplotypes met Bonferroni-corrected significance.

From a genetic epidemiology standpoint, an OR of approximately 12 represents a substantial effect size. As Krantz noted in the interview, most common-disease genetic associations yield ORs between 1 and 2. The magnitude of association here supports biologic plausibility and positions HLA-A*32:01 as a meaningful risk marker.

At the amino acid level, the investigators identified 2 significant HLA-A positions associated with DRESS: lysine at position 109 (OR, 2.4; 95% CI, 1.5–3.3; Pc < .001) and serine at position 77 (OR, 1.9; 95% CI, 1.0–2.7; Pc < .001). These findings suggest that structural features of the HLA-A molecule may contribute to altered peptide presentation and T-cell activation in lamotrigine hypersensitivity.

Despite the strength of the association, Krantz emphasized that translation into routine pre-prescription screening requires careful consideration of predictive value.

“At this point, what inhibits the ability to really implement HLA testing in the clinic is that while it may have a decent negative predictive value, meaning that if you do not carry the risk allele you're much less likely to develop the disease, it doesn't completely exclude it,” Krantz said, “That’s some work that needs to continue to be done before this can really be translated into the clinic where clinicians are using it for pre-prescription testing.”

Relevant disclosures for Krantz include Silk Road Medical, Inc., Boston Scientific Corporation, and Tactile Systems Technology Inc.

Krantz M, Gangula R, Yu A, et al. HLA-A*32:01 carriage is associated with lamotrigine-induced drug reaction with eosinophilia and systemic symptoms in a US cohort. 

Journal of Allergy and Clinical Immunology

. 2026;157(2):AB428. doi:https://doi.org/10.1016/j.jaci.2025.12.953

Videos

Prospective case-control data presented at AAAI 2026 demonstrate a 12-fold increased odds of DRESS among lamotrigine-treated HLA-A*32:01 carriers.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Gerald Appel, MD, is a professor of clinical medicine, director of clinical nephrology, and director of the Glomerular Disease Center at Columbia University.

Luis Sanchez Russo, MD, is a nephrologist affiliating with Advent Health.

Associate Professor, Drexel University, Co-Director Autoimmune Kidney Disease Center, Allegheny Health Network

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

Rare Disease Day 2026: Kidney Diseases Enter Optimistic Therapeutic Era

On Rare Disease Day 2026, 4 clinicians share their insights and perspectives on the groundbreaking improvements in the rapidly evolving field of rare kidney diseases.

Despite persistent awareness gaps in rare kidney disease care, a wave of FDA approvals and phase 3 trial successes in 

 alongside updated 2025 KDIGO Practice Guidelines, has fueled growing clinician optimism about a rapidly advancing, disease-modifying treatment era.

Rare kidney diseases remain complex and underrecognized, leaving both patients and clinicians with challenges in early diagnosis, risk stratification, and long-term management. Yet recent scientific advances and regulatory approvals are beginning to reshape the therapeutic landscape.

Momentum in rare kidney disease care has accelerated with multiple FDA approvals supported by pivotal clinical trial data. In IgAN, 

demonstrated significant reductions in proteinuria and preservation of kidney function in the NefIgArd trial, while 

, a dual endothelin-angiotensin receptor antagonist, showed positive outcomes in the PROTECT study. The addition of 

, an endothelin A receptor antagonist, further underscores the diversification of therapeutic strategies in IgAN, with the ALIGN Phase III trial demonstrating clinically meaningful reductions in proteinuria, a key surrogate for slowing disease progression. Iptacopan, a factor B inhibitor targeting the alternative complement pathway, reported encouraging efficacy in the APPLAUSE-IgAN trial, highlighting a precision-based approach to treatment.

In C3G, iptacopan also showed promising results in the 

, alongside other complement-targeted therapies such as 

 and danicopan, reflecting growing opportunities for disease modification in a previously limited treatment space.

These advances are complemented by the updated 

, which provide evidence-based recommendations to support clinicians in diagnosis, monitoring, and treatment selection, fostering a more standardized and patient-centered approach.

Together, these therapies, spanning endothelin-angiotensin signaling modulation, complement inhibition, and targeted anti-inflammatory strategies, illustrate a shift toward precision medicine in rare kidney disease. 

6 New Kidney Disease Medications Approved in 2025. National Kidney Foundation. Published January 21, 2026. 

https://www.kidney.org/news-stories/6-new-kidney-disease-medications-approved-2025

Sayna Norouzi, MD, Cheung K, Skolnik E, Peleg Y. 2025 KDIGO Guideline Update for IgAN. Hcplive.com. Published January 14, 2026. Accessed February 28, 2026. https://www.hcplive.com/view/2025-kdigo-guideline-update-for-igan

Perkovic V, Barratt J, Rovin BH, et al; APPLAUSE‑IgAN Investigators. 

Alternative complement pathway inhibition with iptacopan in IgA nephropathy.

 N Engl J Med. 2025;392(6):531‑543. doi:10.1056/NEJMoa2410316. Published online 2024 Oct 25.

Kavanagh D, Bomback AS, Vivarelli M, et al. 

Oral iptacopan therapy in patients with C3 glomerulopathy: a randomized, double‑blind, placebo‑controlled, phase 3 study.

 Lancet. 2025;406(10512):1587‑1598. doi:10.1016/S0140‑6736(25)01148‑1.

Lafayette R, et al; NefIgArd Investigators. 

Efficacy and safety of a targeted‑release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2‑year results from a randomized phase 3 trial.

KDIGO IgAN and IgA Vasculitis Work Group; Rovin BH, Barratt J, Cook HT, et al. 

KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

 Kidney Int. 2025;108(4S):S1‑S71. doi:10.1016/j.kint.2025.04.004.

Novartis receives FDA accelerated approval for Fabhalta (iptacopan), the first and only complement inhibitor for reduction of proteinuria in adults with primary IgA nephropathy.

Novartis investigational atrasentan Phase III study demonstrates clinically meaningful proteinuria reduction in patients with IgA nephropathy (ALIGN).

On Rare Disease Day 2026, clinicians share their perspective on the evolving landscape for IgAN and C3G. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

GLP-1s Linked to Reduced Asthma Exacerbations, With Ruchi Patel, MD

Initiation of glucagon-like peptide-1 (GLP-1) receptor agonists was associated with a significantly lower risk of 

exacerbations in non-diabetic patients with overweight and obesity, according to research presented at the 2026 

Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) 

in Philadelphia from February 27 – March 2.

 spoke with Ruchi Patel, MD, from Rutgers NJMS, on the clinical implications of these findings, including the magnitude of asthma exacerbation reduction clinicians might expect when initiating GLP-1 therapy and whether asthma specialists should take a more proactive role in discussing GLP-1 receptor agonists with primary care physicians.

“I think a lot of the primary care providers and obesity specialists [are] pretty aware of the GLP-1s already, but definitely, if the patient comes to a specialist, and it hasn't been brought up yet, it's a really good thing to bring up,” Patel said.

The study included non-diabetic patients with asthma categorized as overweight (BMI 25.00–29.99 kg/m²), obese (BMI 30.00–40.00 kg/m²), or morbidly obese (BMI ≥40.00 kg/m²). After propensity score matching, the overweight cohort included 710 patients, the obese cohort 1,515 patients, and the morbidly obese cohort 1,249 patients.

In an analysis using the TriNetX global research network, Patel and colleagues observed absolute risk reductions ranging from 12.2% to 14.6% over a 3-year follow-up period among patients who initiated a GLP-1 receptor agonist compared with matched controls without GLP-1 exposure.¹

“To translate it into more of a real world number, that's 12 to 15 less exacerbations per 100 patients that are treated with the GLP-1,” Patel said.

GLP-1 initiation in the overweight group was associated with a risk ratio (RR) of 0.748 and an absolute risk reduction of 14.6%. In the obese group, the RR was 0.790 with a 12.2% absolute risk reduction, while in the morbidly obese group, the RR was 0.780 with a 13.3% absolute risk reduction.¹

Obesity is a well-established modifier of asthma severity and control, with patients often experiencing increased symptom burden and exacerbation risk. Weight loss interventions, including bariatric surgery, have previously been associated with improvements in asthma outcomes.

However, GLP-1 receptor agonists have not been incorporated into asthma management strategies, and their potential respiratory effects remain under investigation.

In discussing the mechanism behind the observed association, Patel cautioned that the reduction in exacerbations likely reflects more than one pathway. “It’s probably a bit of both,” she said, referring to weight loss and potential anti-inflammatory effects of GLP-1 receptor agonists. “The reason why I think it's not just weight loss and it's also the anti-inflammatory effects of the GLP-1 is because even in our overweight category, where I would have expected a more modest weight loss, their results stayed pretty consistent compared to the other BMI category. That makes me think it's not just weight loss, but also the anti-inflammatory effects of the GLP-1.”

Patel R, et al. GLP-1 receptor agonists associated with reduced asthma exacerbation in patients without diabetes. Presented at American Academy of Allergy, Asthma & Immunology Annual Meeting; February 27–March 2, 2026 in Philadelphia, PA. Published in online supplement of 

https://www.aaaai.org/about/news/news/2026/glp1

Mawlichanów M, Tatara P, Kwiatkowski A, Różańska-Walędziak A, Walędziak M. Bariatric Surgery in Asthma: A Narrative Review. 

. 2024;60(5):806. Published 2024 May 14. 

Retrospective analysis presented at AAAAI 2026 found 12%–15% risk reductions in asthma exacerbations over 3 years among patients without diabetes with overweight and obesity.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

What CAFETERIA Means for Long-Term OIT Goals, with Scott Sicherer, MD

Months after topline results from the CAFETERIA study demonstrated the ability to instill high levels of tolerance in children with high-threshold peanut allergy, questions remain about how its findings fit within traditional oral immunotherapy (OIT) goals and how it highlights the distinction between desensitization and sustained unresponsiveness.

The CAFETERIA study was highlighted in a session given by Scott H. Sicherer, MD, Director of the Elliot and Roslyn Jaffe Food Allergy Institute and the Elliot and Roslyn Jaffe Professor of Pediatric Allergy and Immunology at the Icahn School of Medicine at Mount Sinai, at the 

 2026 Annual Meeting held in Philadelphia, Pennsylvania.

sat down with Sicherer to discuss how clinicians should interpret the study’s results in real-world practice. He noted that terms like “remission” and “sustained unresponsiveness” are often used loosely, but in research they are highly protocol-specific. In many OIT trials, sustained unresponsiveness is defined by a relatively short avoidance period of often 6 weeks before re-challenge. In CAFETERIA, the team sought to mirror a more realistic scenario. After children demonstrated the ability to tolerate the equivalent of a peanut butter sandwich, they were asked to incorporate peanut more naturally into their diets for 16 weeks, consuming modest amounts weekly rather than adhering to a strict daily regimen. Only after that period were they instructed to completely avoid peanut for eight weeks before undergoing a final oral food challenge.

Most participants maintained tolerance after that extended, real-world–informed approach. Still, Sicherer is cautious about framing the results as a “cure.” In practice, he continues to counsel families that ongoing ingestion is important. Even if 1 to 2 tablespoons per week appears sufficient to maintain benefit, prolonged avoidance could allow clinical reactivity to return. For that reason, he advises continued dietary inclusion and routine follow-up rather than declaring the allergy resolved.

While CAFETERIA was a single-site study can not be generalized across food allergies, Sicherer believes the core principle of the study, that individuals with lower baseline IgE levels and higher initial tolerance thresholds may respond more readily to low-intensity OIT, likely extends beyond peanut. The concept may be applicable to other common allergens such as milk, egg, or tree nuts and would benefit from broader replication. Whether larger, multi-center trials will test that hypothesis remains to be seen, but the phenotype-driven approach introduced by CAFETERIA may signal a broader evolution in food allergy management.

“There's nothing so special about peanut. In fact, it might be that peanut would have been a harder case to approach. So would this apply to egg or milk or or other nuts and just other foods in general? I think the answer is yes. But are the studies going to be done? We'll wait and see,” Sicherer said.

Sicherer SH, Bunyavanich S, Berin MC, et al. Peanut Oral Immunotherapy in Children with High-Threshold Peanut Allergy. 

. Published online February 10, 2025. doi: 10.1056/evidoa2400306

Sicherer S. FAED Presents: The Potential for Tolerance After Oral Immunotherapy in High-Threshold Patients: The CAFETERIA Study. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Session 1705.

Sicherer discussed how the study might shift clinical thinking in pediatric food allergy. 

Navepegritide, to be marketed as YUVIWEL, is the only FDA-approved treatment providing continuous CNP exposure over its weekly dosing interval.

FDA News

Family Medicine

Family Medicine condition center page, resources on the topics of medical news and expert insight into family care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on Family medicine research, treatment, and drug development.

FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older

an internal medicine and pediatrics-trained allergist practicing in Mobile, Alabama.

Once-daily VTAMZA delivers week-one sleep gains and lasting itch control in atopic dermatitis, with safety consistent across studies.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

What to Expect for Sleep Improvement With Tapinarof in AD, With Druhan Howell, MD

UChicago GI faculty bring expert endoscopy and IBD care closer to you, with seamless hospital follow-up and cutting-edge clinical trials.

Expanding Access, Advancing Science- How the University of Chicago Is Redefining IBD Care Across Chicagoland

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The long-acting growth hormone is now indicated for children aged 2.5 years and older with Idiopathic Short Stature, born Small for Gestational Age, or Noonan Syndrome.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

FDA Approves 3 New Pediatric Indications for Once-Weekly Somapacitan-beco (Sogroya)

Post hoc pooled data from ADORING 1 and 2 demonstrate statistically significant improvements in patient and family sleep scores in children aged 2–17 years

Tapinarof Cream 1% Improves Sleep in Atopic Dermatitis, With Druhan Howell, MD

Sicherer discussed how findings from CAFETERIA may inform treatment decisions for children with high-threshold allergy.

CAFETERIA: Expanding Treatment Pathways for High-Threshold Peanut Allergy, with Scott Sicherer, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

These new data from the OLYMPIA open-label extension study highlight long-term safety and efficacy findings on nemolizumab (Nemluvio).

Nemolizumab Shows Long-Term Efficacy in Prurigo Nodularis for Up to 3 Years

Mohammad Anadani, MD, is the chief of neuroendovascular services for Intent Medical Group at the Endeavor Health Advanced Neurosciences Center.

Anadani discusses a recent study highlighting the myriad contributing factors in the steadily increasing risk of maternal stroke across the country.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Pregnancy-Related Maternal Stroke Increasing Across US, With Mohammad Anadani, MD

Adrian Brown, PhD, NIHR Advanced Fellow and Associate Professor in Nutrition and Dietetics at University College London and programme co-lead of the MSc Dietetics (Pre-registration) course

Brown discusses a destigmatised future of obesity management in patients with kidney failure. 


Chronic Kidney Disease

Destigmatizing Obesity in Kidney Failure Patients Seeking Transplants, With Adrian Brown, PhD

Bhatt discusses a recent study from GSK highlighting AREXVY’s efficacy in lowering major adverse cardiovascular events.

Latest News

Mepolizumab Reduces Type 2 COPD Exacerbations Across Variable BEC Levels

HLA-A*32:01 Linked to Lamotrigine DRESS Risk, With Matthew Krantz, MD

Rare Disease Day 2026: Kidney Diseases Enter Optimistic Therapeutic Era

GLP-1s Linked to Reduced Asthma Exacerbations, With Ruchi Patel, MD

What CAFETERIA Means for Long-Term OIT Goals, with Scott Sicherer, MD